NVAX -Cadila Pharma Ltd and Novavax in collaboration on the H1N1 Vaccine:January 5, 2010CPL is in the process of completing a vaccine manufacturing facility to produce H1N1 vaccine using the virus like particles (VLP) technology in collaboration with the US-based company, Novavax.
CPL Biologicals Pvt Ltd, the newly formed joint venture between Cadila Pharma and Novavax, expects to start producing the H1N1 swine flu vaccine in the next three-four months. At present, the H1N1 vaccine market is estimated to be 676 million dollars. The market is expected to cross the 7 billion dollar mark by 2011
www.indianexpress.com/news/ahmeda...
March 12, 2010 CC:CPL Biologicals is currently building a 25,000 square feet, state of the art vaccine and biological manufacturing facility for production of our vaccine and other products, and is expected to complete around the April-May timeframe. In addition, as this facility is being built according to the U.S. and European standards, it will meet all the criteria for the product to be sold in other parts of the world.
www.novavax.com/download/File/Tra...
Novavax Announces Completion of Construction of Vaccine Production Facility in India • CPL Biologicals state-of-the-art vaccine facility operational in Dholka, India • Validation testing to begin this month
• Annual bulk production capacity projected at 60 million doses of VLP influenza vaccine
• Sterile filling capacity available
ROCKVILLE, MD - June 10, 2010 - CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. and Novavax, Inc. (Nasdaq: NVAX), today announced that it has completed construction of its vaccine facility in Dholka, India and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use.
About Cadila Pharmaceuticals Ltd. Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. Cadila Pharmaceuticals is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art research and development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering.
The company also participates in public-private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has state-of-the-art manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the world map with the development of Polycap - a novel and world’s first drug combination for primary prevention of cardiovascular heart disease (CHD).
About Novavax Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website:
www.novavax.com.
The new facility utilizes state-of-the-art equipment for fast and efficient production of up to potentially 60 million doses of novel vaccines every year. Mr. I. A. Modi, Chairman of Cadila Pharmaceuticals, said, "This facility demonstrates our commitment to establishing the highest-quality vaccine production facility for our nation. It utilizes world-class design and equipment that will be competitive with the world’s leading vaccine companies."
The facility plans to produce seasonal and pandemic flu vaccines based on Novavax’s advanced virus-like particle (VLP) technology which enables the rapid development and production of novel vaccines without the use of live virus.
Dr. Rahul Singhvi, President and CEO of Novavax, stated: "We congratulate our colleagues at CPL Biologicals on reaching this important milestone in the development of a state-of-the-art vaccine production facility. This achievement reflects our strategy to partner with leading pharmaceutical companies around the world to develop world-class, in-country vaccine-production capacity and use our novel vaccine technology to solve critical public health problems. This world class vaccine production plant in India will be able to supply India and other countries with novel vaccines against influenza and other infectious diseases by using an efficient, reliable and flexible vaccine production process."
In addition to vaccine production, CPLB is also focused on the development, manufacture and sale of biosimilars and diagnostic kits.
About CPL Biologicals CPL Biologicals is a joint venture between Cadila Pharmaceuticals Ltd. and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals. CPL Biologicals has the infrastructure ready for its state-of-the-art manufacturing facility at Dholka, near Ahmedabad, in the state of Gujarat, India with a focus on developing, producing and marketing seasonal and pandemic flu vaccines based on Novavax’s virus-like-particle (VLP) vaccine technology. CPL Biologicals will also produce biosimilars and diagnostic kits.
About Cadila Pharmaceuticals Ltd. Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. Cadila Pharmaceuticals is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art research and development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering.
The company also participates in public-private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has state-of-the-art manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the world map with the development of Polycap - a novel and world’s first drug combination for primary prevention of cardiovascular heart disease (CHD).
Wednesday, July 21, 2010, 5:22pm EDTAkridge sells D.C. condo to Cadila Pharmaceuticals
Washington Business Journal -
Akridge has sold the last office condominium in its 1016 16th St. NW boutique office property to Cadila Pharmaceuticals Ltd. for $1.38 million.
India-based Cadila bought 2,232 square feet for about $618 per square foot.
Akridge bought the eight-story building in 2006 and renovated it the following year. The structure, which sits near the intersection of 16th and K streets, dates back to the 1920s.
Akridge has sold office condominiums in the building to groups such as The Thomas B. Fordham Institute and the Jesuit Conference.
Last year, Cadila had entered into a joint venture with Rockville-based Novavax Inc. to build a manufacturing site and develop the latter company’s seasonal and pandemic influenza vaccine products in India.
CONNECT THE DOTS SHAREHOLDERS!! 
